近日，澳大利亚驻华大使吉思德访问广州。他表示，广州是一座历史悠久又充满活力的城市，澳中合作 的很多领域都与广州息息相关，希望进一步加强与广州在经贸投资、绿色发展、医疗科技等领域交流合 作，更好实现互利共赢、造福两地人民。 据了解，从2003年到2007年，吉思德曾在澳大利亚驻华大使馆工作。时隔20年，他再次来到中国。吉思 德向21世纪经济报道记者表示，他两次在北京工作相隔20年，期间，北京发生了巨大变化，城市更绿 了，环境也更加安静；同样的情况还发生在中国许多城市。这表明，中国经济不仅快速发展，而且城市 也变得更靓丽、更宏大、更富活力。中国正在稳步推进高质量经济发展。在此新形势下，吉思德认为， 中澳合作可以聚焦三个领域，一是将传统合作转化为新产业（300832）领域的合作，如钢铁产业，二是 医疗技术，三是旅游业。 南方财经21世纪经济报道记者胡慧茵广州报道 ...

编辑丨王多鱼 排版丨水成文 前列腺癌 是全世界男性第二大癌症，随着中国人口老龄化和生活方式的西化，近年来我国前列腺癌发病率以每年 13% 的增速狂飙，现已位居我国男性恶性肿瘤 第六位，且发病率增速还在持续攀升 。 2024 年我国前列腺癌新发病例数达到 14.4 万人，预计 2030 年将达到 19.9 万人， 2035 年将达到 25 万人 。 前列腺癌的诊断主要依赖于血液前列腺特异性抗原 （ PSA ） 、 B 超和医生的直肠指诊。然而临床实践发现： 50 岁以上健康男性体检中， 1/3 的男性 B 超发 现有前列腺结节，近 10% 出现 PSA 异常升高，这些大量的"可疑患者"给临床诊断带来极大的困难，也给"患者"带来了巨大的心理压力。目前，全球各大临床指 南推荐磁共振检查 （ PI-RADS 评分 ） 进一步确诊，并据此进行前列腺穿刺活检来最终确定患者的诊断结果 。 然而，磁共振 PI-RADS 评分 存在两大缺陷： 1 ） 主观性缺陷 —— 该评分 本质 上 依赖放射科医生经验判断。以往研究显示 不同 医生间判读差异高达 30% 。这种主观偏差使精准诊断如同 " 轮盘赌局 "—— 患者可能因假阴性延 ...

Summary of 4DMedical (4DX) Update / Briefing September 01, 2025 Company Overview - **Company**: 4DMedical (4DX) - **Product**: CTVQ, a non-contrast ventilation and perfusion imaging technology - **FDA Approval**: Recently received FDA approval, marking a significant milestone for the company [1][15] Industry Insights - **Market Opportunity**: - The U.S. market for nuclear VQ scans is over $1.1 billion annually, with a global opportunity estimated at $2.6 billion [2] - CTVQ is expected to displace nuclear VQ scans and expand functional imaging due to its scalability and existing infrastructure [3][28] Core Technology Advantages - **No Contrast Agents**: CTVQ eliminates the need for contrast agents, providing clearer and faster diagnostics [4] - **Accessibility**: With 14,500 CT scanners in the U.S., CTVQ can be deployed without the need for new infrastructure [3][28] - **Cost Efficiency**: The technology offers lower costs of care and improved economics for healthcare providers [4][14] Clinical Validation and Performance - **Clinical Evidence**: The FDA approval was supported by robust clinical evidence, including quantitative performance assessments and qualitative evaluations by expert radiologists [16][18] - **Comparison with Existing Technologies**: CTVQ demonstrated strong agreement with SPECT VQ scans, with a statistical analysis showing high correlation [19][25] Commercial Strategy - **Market Readiness**: The company is ready for rollout following FDA approval, with established relationships and evidence to support clinical adoption [32][34] - **Partnerships**: 4DX is leveraging partnerships, including with Philips, to enhance market penetration [34][52] - **Target Hospitals**: The company has identified key hospitals with high volumes of nuclear VQ scans, such as UCSD and Cleveland Clinic, for initial commercialization efforts [35] Financial Projections - **Pricing Strategy**: Expected pricing for the CTVQ scan is around $600 per procedure, with a cost of delivery estimated at $4 [43] - **Revenue Potential**: With an annualized run rate of 300,000 scans, potential revenue could reach $300 million [49][51] Challenges and Market Dynamics - **Transition from Nuclear Medicine**: While there is strong interest, challenges include contracting and IT connectivity with existing providers [44] - **User Adoption**: The technology is designed to integrate seamlessly into existing workflows, minimizing barriers for radiologists [56] Future Outlook - **Reimbursement Timeline**: The company anticipates achieving reimbursement for CTVQ within the year, which would further accelerate market adoption [38][39] - **Global Expansion**: While focusing on the U.S. market, 4DX has ambitions for international expansion once the domestic market is established [59] Conclusion - **Strategic Positioning**: 4DMedical is well-positioned to capitalize on a significant market opportunity with its innovative CTVQ technology, aiming to improve patient outcomes and streamline healthcare processes [30][61]

Market Overview - The London Stock Exchange's FTSE 100 index closed at 9265.80 points, down 55.60 points, representing a decline of 0.60% from the previous trading day [1] - All three major European stock indices experienced declines on the same day [1] Sector Performance - Service sector stocks led the gains in the London stock market, with the top five performers being: - Bunzl, a supply chain services provider, up 5.12% - Fresnillo, a precious metals producer, up 3.08% - Babcock International, an enterprise outsourcing service provider, up 2.10% - BT Group, up 1.60% - Halma, a hazardous materials testing company, up 1.60% [1] - Consumer sector stocks were the biggest losers, with the top five decliners being: - Dunelm Group, a home goods supplier, down 4.34% - Convatec, a medical technology company, down 4.04% - Associated British Foods, down 3.98% - DCC, a marketing and business services company, down 3.47% - Diageo, a beverage company, down 2.88% [1] Other European Indices - The CAC 40 index in Paris closed at 7709.81 points, down 133.23 points, a decline of 1.70% [1] - The DAX index in Frankfurt closed at 24152.87 points, down 120.25 points, a decline of 0.50% [1]

Group 1 - The core index of the London stock market, the FTSE 100, closed at 9265.80 points, down 55.60 points or 0.60% from the previous trading day [1] - The service sector stocks led the gains in the London stock market, with notable increases including: Bunzl up 5.12%, Fresnillo up 3.08%, Babcock International up 2.10%, BT Group up 1.60%, and Halma up 1.60% [1] - Consumer sector stocks experienced the largest declines, with significant drops including: Dunelm down 4.34%, Convatec down 4.04%, Unilever down 3.98%, DCC down 3.47%, and Diageo down 2.88% [1] Group 2 - The CAC40 index in Paris closed at 7709.81 points, down 133.23 points or 1.70% from the previous trading day [1] - The DAX index in Frankfurt closed at 24152.87 points, down 120.25 points or 0.50% from the previous trading day [1]

Core Viewpoint - The stock price of Senseonics Holdings (SENS) has been on a bearish trend, losing 8.3% over the past week, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottom in the stock price, suggesting that selling pressure may be exhausting [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, signaling that bears may be losing control over the price [4][5]. - This pattern can occur across various timeframes and is utilized by both short-term and long-term investors [5]. Fundamental Analysis - There is rising optimism among Wall Street analysts regarding the future earnings of Senseonics, which supports the potential for a trend reversal [2]. - Over the last 30 days, the consensus EPS estimate for the current year has increased by 4.5%, indicating that analysts expect better earnings than previously predicted [8]. - Senseonics currently holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10]. Indicators of Turnaround - An upward trend in earnings estimate revisions is a bullish indicator for Senseonics, as these revisions are strongly correlated with near-term stock price movements [7]. - The Zacks Rank serves as a timing indicator, suggesting that the company's prospects are beginning to improve, further supporting the potential for a turnaround [10].

Core Viewpoint - Anika Therapeutics has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the consensus measure of EPS estimates from sell-side analysts, reflecting the company's changing earnings picture [1][2]. - Changes in future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [3][5]. Institutional Investor Influence - Institutional investors utilize earnings estimates to determine the fair value of a company's shares, impacting stock price through their large transactions [3]. Business Improvement Indicators - Rising earnings estimates and the Zacks rating upgrade suggest an improvement in Anika's underlying business, which could lead to higher stock prices as investors respond positively [4][9]. Earnings Estimate Revisions for Anika - Anika is projected to earn -$0.14 per share for the fiscal year ending December 2025, with no year-over-year change [7]. - Over the past three months, the Zacks Consensus Estimate for Anika has increased by 7.8% [7]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [6][8]. - Anika's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for near-term price appreciation [9].

Core Viewpoint - The event in Wuhan on August 18 celebrated the eighth Chinese Physician's Day and showcased the first batch of 112 core medical technologies, aiming to create a quality platform for medical technology innovation [1][2]. Group 1: Medical Technology Highlights - A total of 112 core medical technologies were released, categorized into three levels: 32 "Leading Technologies," 40 "Pioneering Technologies," and 40 "Fundamental Technologies" [1]. - "Leading Technologies" include world-first innovations such as the "Chen's pancreatic-intestinal anastomosis" technique and the "micro life pump" providing the lightest artificial heart globally [1]. - "Pioneering Technologies" feature advancements like a corneal transplantation technique that can treat three patients with one donated cornea and a "bionic multi-organ chip" technology that can replace human drug testing [1]. - "Fundamental Technologies" focus on widely applicable techniques, such as a "super minimally invasive" technique for immediate stone removal and a technique for acute ischemic stroke intervention that can be taught to clinicians through short-term training [1]. Group 2: Support Measures and Competitive Edge - The Wuhan Municipal Health Commission plans to implement support measures in platform construction, insurance policies, professional title promotions, funding, and publicity to enhance the impact of these technologies [1]. - The evaluation of core medical technologies highlights Wuhan's competitive edge in various fields, particularly in hepatobiliary and gastrointestinal diseases, gynecological tumors, organ transplantation, cardiovascular diseases, and urological diseases [2]. - The application of cutting-edge technologies such as brain-computer interfaces, artificial intelligence, stem cell therapy, and biomaterials in Wuhan demonstrates significant breakthrough potential [2].

Core Insights - Wuhan has launched its first batch of core medical technologies, marking a significant step in establishing itself as an international medical innovation hub [1] - A total of 112 core medical technologies were released, with 617 projects submitted by 39 medical institutions during the evaluation process [1][2] - The technologies span various fields, showcasing high competitiveness in organ transplantation, gastrointestinal diseases, gynecological tumors, and cardiovascular diseases [1] Technology Classification - The 112 core medical technologies are categorized into three groups: - 32 "Leading Technologies" represent breakthrough innovations, including the globally recognized Chen's liver blood flow blockade method and the world's lightest artificial heart technology [2] - 40 "Pioneering Technologies" focus on improving traditional methods to address significant medical challenges, such as a corneal transplant technique that treats three patients with one donated cornea [2] - 40 "Fundamental Technologies" target common diseases and are suitable for widespread use in primary healthcare settings, like the "super minimally invasive" technique for immediate stone removal [2] Support Measures - The Wuhan Municipal Health Commission will implement support measures for the selected 112 core medical technologies, including platform development, insurance policies, professional title promotions, funding, and promotional activities [2]

Core Viewpoint - Cardinal Health announced the acquisition of UroGen Pharma for $1.9 billion, leading to a decline in its stock price [1] Group 1: Acquisition Details - The acquisition is a cash transaction valued at $1.9 billion [1] - UroGen Pharma is valued at $16 per share, representing a 14% premium over its closing price on Tuesday [1] Group 2: Market Reaction - Following the announcement, Cardinal Health's stock price initially dropped by 4.2% during trading [1] - The stock ultimately closed down 2.7% at $102.45 [1]